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Background: The androgen receptor plays a critical role throughout the progression of prostate cancer and is an
important drug target for this disease. While chromatin immunoprecipitation coupled with massively parallel
sequencing (ChIP-Seq) is becoming an essential tool for studying transcription and chromatin modification factors,
it has rarely been employed in the context of drug discovery.
Results: Here we report changes in the genome-wide AR binding landscape due to dose-dependent inhibition by
drug-like small molecules using ChIP-Seq. Integration of sequence analysis, transcriptome profiling, cell viability
assays and xenograft tumor growth inhibition studies enabled us to establish a direct cistrome-activity relationship
for two novel potent AR antagonists. By selectively occupying the strongest binding sites, AR signaling remains
active even when androgen levels are low, as is characteristic of first-line androgen ablation therapy. Coupled
cistrome and transcriptome profiling upon small molecule antagonism led to the identification of a core set of AR
direct effector genes that are most likely to mediate the activities of targeted agents: unbiased pathway mapping
revealed that AR is a key modulator of steroid metabolism by forming a tightly controlled feedback loop with other
nuclear receptor family members and this oncogenic effect can be relieved by antagonist treatment. Furthermore,
we found that AR also has an extensive role in negative gene regulation, with estrogen (related) receptor likely
mediating its function as a transcriptional repressor.
Conclusions: Our study provides a global and dynamic view of AR’s regulatory program upon antagonism, which
may serve as a molecular basis for deciphering and developing AR therapeutics.
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Prostate cancer is the second most commonly diagnosed
cancer and the second leading cause of cancer mortality
in men in the United States. Despite decades of research,
there are no effective treatment options available for the
advanced stages of the disease. While androgen ablation
therapy is a standard first-line treatment, the vast major-
ity of prostate tumors eventually become hormone re-
fractory and continue to proliferate even with very low
levels of androgen. This stage, often referred to as* Correspondence: Zhou.Zhu@pfizer.com; andrea_fanjul@hotmail.com
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reproduction in any medium, provided the orcastration-resistant prostate cancer (CRPC), is associated
with an active androgen receptor (AR)-signaling path-
way. Chen et al. reported that in human prostate cancer
cell lines and xenografts derived from metastatic lesions,
AR over-expression is necessary and sufficient to render
the cells resistant to androgen withdrawal and antian-
drogens [1]. The observation is further supported in the
clinical setting where AR is frequently over-expressed in
CRPC with AR amplification in up to 30% of those
tumors [2-4].
AR, a member of the nuclear receptor (NR) superfam-
ily, functions mainly as a ligand-dependent transcription
factor. Upon binding of the androgenic hormone testos-
terone or its more active analog dihydrotestosterone. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2164/13/355(DHT) in the cytoplasm, AR translocates into the nu-
cleus to bind DNA and regulate gene expression. AR has
a wide range of regulatory roles in prostate growth and
function, including but not limited to cellular prolifera-
tion, differentiation, apoptosis, metabolism and secretory
activity [5]. While many of its direct activation targets
have been characterized, the key downstream effectors,
especially those playing a role in carcinogenesis or
modulated during targeted therapy, remain to be deter-
mined; even less is known about the genes directly
repressed by AR [6], though they may also be important
contributors to AR function in disease and treatment
settings.
Currently approved drugs aimed at androgen signaling
axis include the AR antagonist bicalutamide and the
CYP17 inhibitor abiraterone [7]. Given the critical role
of AR in prostate cancer progression and particularly
the late stages of the disease, additional therapeutic
approaches are under development to target the recep-
tor. Preclinical strategies involve double-stranded RNA
interference, microinjection of anti-AR antibodies, and
antisense oligonucleotides [2]. The most advanced
agents in clinical testing are second-generation small
molecule antagonists of AR function such as the dia-
rylthiohydantoin MDV3100, which reduces the efficiency
of AR nuclear translocation and impairs both DNA
binding and recruitment of coactivators [8,9].
Recent advances in high throughput technologies such
as ChIP-Chip and ChIP-Seq have enabled genome-wide
identification of the AR cistrome in a number of preclin-
ical models of prostate cancer [10-13]. While these stud-
ies provided novel insights into AR biology and gene
regulatory networks, some important questions remain
to be answered. In particular, the genomic landscape of
AR binding has not been published in the presence of
pharmacological agents, which are key to understanding
the molecular activity of AR therapeutics. Furthermore,
neither the core set of direct effector targets upon which
AR’s binding and transcriptional activities are modulated
by inhibitor drugs nor the oncogenic pathways they rep-
resent have been identified.
In this work, we employ chromatin immunoprecipita-
tion coupled with massively parallel sequencing (ChIP-
Seq) to provide the first publicly available genome-wide
and dose-dependent inhibition map of AR binding by
small molecules. By integrating sequence analysis, tran-
scriptome profiling, cell viability assays and xenograft
tumor growth inhibition studies, we explore the AR
cistrome-activity relationship to render a global and dy-
namic view of its regulatory program upon small mol-
ecule antagonism. We also investigate endogenous and
wild type AR binding at low androgen levels, a scenario
that mimics prostate cancer patients following first-line
androgen ablation therapy. Collectively, our study offersmolecular insights into the pathological role of AR in
CRPC progression and therapeutic-like contexts.
Results
A spectrum of genome-wide AR binding in VCaP cells
To create high-resolution, global maps of the interactions
between DNA and androgen receptor, we profiled the
VCaP cell line, which was derived from a vertebrate me-
tastasis of a 59 year old male with CRPC. With high
levels of endogenous wild type AR and TMPRSS2-ERG
fusions as well as expression of many prostate epithelial
markers, these cells serve as a useful model for CRPC
tumor progression and metastasis [14,15]. VCaP cells
were grown in the presence (+) or absence (−) of the syn-
thetic AR agonist metribolone (R1881) to characterize
AR binding in high and low androgen conditions respect-
ively. Cross-linked chromatin from VCaP cells was
immunoprecipitated with an antibody (H-280) highly
specific for AR, which recognized a single major band at
110 kb on western blot and the same band was reduced
by AR-siRNA treatment (Additional file 1: Figure S1).
DNA pull-downs were then purified, amplified and
sequenced with the Illumina Genome Analyzer 2, result-
ing in approximately 50 million single-end reads from
each sample, which were then mapped to the most recent
version of the human genome (hg19) with the ELAND
algorithm.
Using Model-based Analysis of ChIP-Seq (MACS)
[16], we identified 49998 and 15414 AR binding sites for
R1881(+) and R1881(−) samples respectively. For subse-
quent analyses, we focused on the 16907 and 2307 high-
confidence sites (Additional file 2: sFile 1), which had
higher statistical significance than any of the “negative”
peaks obtained by swapping the ChIP-Seq and control
channels. The AR binding at all twelve tested regions
was more than 3-fold above negative control by quanti-
tative PCR analysis (Table 1), suggesting that the sites
identified by ChIP-Seq represent bona fide AR binding.
Additionally, the MACS binding (p-value) score was
concordant (R = 0.87, P = 0.00025) with the enrichment
values from qPCR.
As functional elements tend to be evolutionarily con-
served, we examined the multiple alignments of 45 ver-
tebrate genomes to the human genome by sampling
phastCons conservation score [17,18] every 100 bp. AR
sites were most conserved at their binding summit and
quickly dropped down to near genomic background level
within 300 bp of either side of the summit (Figure 1A),
underscoring the high resolution of ChIP-Seq technology
as well as the accuracy of summit position calls by the
MACS algorithm. Importantly, AR binding sites identi-
fied from R1881(−) sample were no less conserved than
those from R1881(+) sample (Figure 1A), revealing that
Table 1 Real-time quantitative PCR (qPCR) validation of AR binding sites
Genomic coordinates Binding score (MACS) Fold enrichment (MACS) Fold enrichment
over negative
control (qPCR)
Primer sequence (forward) Primer sequence (reverse)
chr start end
negative control TGGACCTTTACCTGCTTTATCA AGCAAGGACTAGGATGACAGAA
1 228856976 228857630 864.12 56.08 3.48 GAGGACACAACCCCATGACT AGAGCGAAACTCCGTCTCAA
2 8808594 8809289 886.86 40.25 5.60 GATGGATGGATGGATGTCTT CTGGTTTTCCAAGCTCACAA
2 237457017 237457622 633.63 26.93 8.63 GCAGGGAGGTCTTTGATCTG TCCTGAATTGGTTTGCTCAT
3 187946846 187947612 665.42 25.52 8.93 CCCATTTGGCTTCTTACTTTGT TTCCTTCCTGACTCCCACTG
4 175441647 175442310 986.29 39.85 23.03 CCAAAATATCATGTGCAATCAA AAACACAATGCAAGAGGAACA
6 35699525 35700397 855.76 36.81 8.01 CGCATAGAAGCTAAGGGGAAAT GATGTGAATGCAAGCCTGTC
6 43721200 43721909 1211.19 40.99 20.88 TGGCCTCTGTCTTTTGTGTT CACAGCTTCCAACTAGCTTTACA
9 82188374 82188956 532.18 26.96 9.22 GTTGCGGGAGGAGAGTTTTA GAAGCAGGGAGACGGAGAAA
10 3852210 3852832 500.44 29.26 12.13 CACCAGCTCCCAACTTTCAG CAGCTTCCACTCCCTGTACC
19 51353679 51354605 3100 94.82 42.11 GTGTTGCTGTCTTTGCTCAG CAGTGTTGGGAGGCAATTCT
20 35888865 35889525 511.25 27.54 3.10 GCAAGACCCCATCTCAAAGA GGCTCGGCTACACTTCATTC
20 56260437 56261119 1605.03 60.05 35.60 CTGGCTGCTCCAGAGAACTA CGGCCACGTACAGTCCTATT



























Figure 1 Comparative analysis of AR binding in low and high androgen levels. (A) Mean sequence conservation profiles based on
phastCons score sampled every 100 bp from the summit of AR binding sites to 10 kb in both directions. The inset provides a zoom-in view of
the profiles in the immediate vicinity of the summit. (B) Over 99% of the sites bound by AR in the absence of R1881 stimuli were also bound in
its presence. (C) AR selectively occupied stronger binding sites in the absence of R1881 stimuli. AR binding sites defined from R1881(+) sample
were divided into two groups based on overlap with R1881(−)-defined sites (Bound: n = 2330; Not Bound: n = 14577). Boxplots depict the
distributions of their binding scores.
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random and likely occupies functional sites.
When AR binding sites were mapped to genomic
annotations, they appeared only moderately associated
with proximal promoters, with approximately 2 fold
over-representation compared to genomic background
(Additional file 3: Table S1). This is consistent with pre-
vious reports that AR often acts through distal enhancer
elements [10,13,19]. Unbiased signature analysis showed
that AR-bound genes were most significantly enriched
with those transcriptionally regulated by the androgen
receptor signaling pathway from mRNA profiling studies
(Additional file 3: Table S2): depending on the exact ex-
pression signature, between 40% and 63% of the genes in
the signature had high-confidence AR binding within
25 kb of their transcription start sites (TSS), whereas
only 23% were expected.
We next performed a comparative analysis of AR
binding in low and high androgen conditions. Strikingly,
with more than 99% of AR binding sites identified in the
absence of R1881 stimuli also bound in its presence
(Figure 1B), the R1881(−) binding sites appeared to be a
near-perfect subset of R1881(+) ones. Furthermore, the
common binding sites were significantly biased towards
those with higher binding score (P< 2.2e-16; Figure 1C
and Figure 5C). Together, our findings reveal that even
in low androgen level situations, such as those charac-
teristic of androgen ablation treatment, AR is still func-
tional by selectively occupying the strongest binding
sites.AR binding and cell type
To investigate the role of cell type in AR binding, we
compared sites identified in VCaP with those from other
pre-clinical models of prostate cancer [10,11,13]. VCaP
and LNCaP (including its androgen-independent deriva-
tive abl) cells share more than 60% of their AR binding
sites regardless of the technology platform (ChIP-Chip or
ChIP-Seq) used for profiling (Additional file 1: Figure S2).
Interestingly, the overlap was even more extensive for
those also occupied in the absence of R1881 stimuli
(Penrichment = 1.33e-192, 9.55e-219 and 2.64e-77 for
LNCaP ChIP-chip, LNCaP-abl ChIP-chip and LNCaP
Chip-seq respectively), implying that “baseline” AR bind-
ing tends to be preferentially conserved across cell types.
By contrast, AR binding in VCaP and PC3-AR cells
were highly discordant and had only 41 sites in com-
mon, corresponding to 0.2% of total VCaP and 0.6% of
total PC3-AR sites. Furthermore, we didn’t observe a
significant enrichment of overlap for the R1881(−) sub-
set (P = 0.19). As both datasets were collected using
ChIP-Seq, this sharp divergence is more likely biological
than technical: PC3 cells do not express androgenreceptor endogenously and its AR binding was profiled
following transfection of an AR construct [11]. Unlike
the binding pattern in endogenous AR-expressing VCaP
and LNCaP cells, the AR binding sites in PC3-AR cells
were reported to be predominantly in the proximal
vicinity of TSS and to lack androgen response elements
(ARE) [11]. These differences underscore the important
role that biological and experimental context plays in
transcription factor binding and function.DNA cis-regulatory element associated with AR binding
A systematic search of known transcription factor bind-
ing motifs curated by the Genomatix MatBase database
(www.genomatix.de) identified cis-regulatory elements
for the GREF (Glucocorticoid responsive and related ele-
ments) family to be most enriched among AR-bound
sequences (Additional file 3: Table S3), with 85% con-
taining at least one copy of the motifs (Z-score = 131.43
and 41.33 for R1881(+) and R1881(−) samples respect-
ively). The GREF family includes the androgen receptor
and the closely related glucocorticoid, mineralocorticoid
and progesterone receptors [20]. FKHD (forkhead do-
main factors) motifs were the second most over-
represented family, consistent with previous reports
[10,13] as well as its proposed role as a pioneer factor
for AR [21]. Interestingly, neighboring GREF and FKHD
elements (10–50 bp) had a clear distance preference at
15 bp (Additional file 1: Figure S3A), indicating a likely
geometric constraint resulting from their interaction.
Cis-regulatory elements for many other AR interacting
factors, such as GATA, HNF1 (Hepatic Nuclear Factor 1)
and NF1F (Nuclear Factor 1), were also highly over-
represented (Additional file 3: Table S3). Additionally,
AR binding sites were enriched with sequence motifs
recognized by the ABDB (Abdominal-B type homeodo-
main transcription factors) family (Additional file 3:
Table S3), suggesting potential combinatorial control be-
tween androgen receptor and homeobox genes. HOXB13
has recently been reported to regulate the cellular re-
sponse to androgens [22] as well as co-localize with AR
to suppress androgen-stimulated PSA expression [23],
while HOXC8 appears to negatively regulate AR signal-
ing in prostate cancer cells by inhibiting SRC-3 recruit-
ment to direct androgen target genes [24].
Ab initio motif discovery with the MEME algorithm [25]
identified a perfectly palindromic 15 bp motif (Additional
file 1: Figure S3B), supporting the observation that AR
interacts with DNA as dimers [20,26]. It was highly spe-
cific to the AR-bound sequences [Z-score= 126.76 and
49.30 for R1881(+) and R1881(−) samples respectively;
Figure 5E] and strongly resembled the androgen re-
sponse element (ARE) described previously [12,13,27].
Furthermore, AR sites with this motif were stronger
(C)
• r = 0.60
• P < 2.2e-16
• r = 0.56
• P < 2.2e-16
(A)
(B)
Figure 2 Novel AR antagonists utilized in this study. (A) Chemical structures (compound number listed below structure). (B) Nuclear
Translocation of AR was impeded by these compounds. LNAR cells were treated with 0.1nM R1881 alone or in combination with the antagonist
compounds at various doses to determine IC50 values. Nuclear translocation values were calculated as indicated under Methods. (C) Treatment of
VCaP cells with small molecule AR antagonist induced similar genome-wide transcriptional effects as AR inhibition by siRNA. Left: fold change
from the two types of treatments; Right: SAM d-score of differential expression from the two types of treatments.
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Figure S3C), underscoring its role in determining AR
binding.
Small molecule inhibitors of AR function
After conducting an extensive structure-activity relation-
ship (SAR) study using a CRPC cell-based high through-
put screening, we identified two novel potent AR
antagonists (Figure 2A) [28]. Importantly, these aryloxy
tetramethylcyclobutane compounds had no agonist ef-
fect up to 10 μM concentration while effectively inhibit-
ing AR translocation from the cytoplasm to the nucleus(Figure 2B and Table 2). Molecular modeling suggested
that these compounds with relatively bulky substituents
at the amide likely extend between Asn705 and Thr877
and force the critical Helix 12 of the AR ligand-binding
domain (LBD) into a disrupted “open” conformation,
thereby leading to AR full antagonism [28].
To confirm that AR is de facto the protein target of
these compounds, we compared the mRNA profiles of
VCaP cells treated with Compound 30 and those treated
with AR-siRNA using the Affymetrix HG-U133Plus2.0
GeneChip array. Differential expression analysis was
conducted with Significance Analysis of Microarray
Table 2 Cell-based profile of AR antagonist compounds
AR agonism (at 1uM) AR antagonism Nuclear Translocation Cell Proliferation
Fold Induction % Inhibition IC50-nM % Inhibition at 1uM IC50-nM IC50-nM
Compound 30 0.83 -0.7 144 90 174 94
Compound 26 1.03 0.1 59 96 57 45
For agonism, values obtained from the AR antagonist compounds were compared to those of untreated cells, which were assigned an arbitrary number of 1.0 to indicate no agonism. For antagonism, cells were
treated with 0.1nM R1881 alone (corresponding to max receptor activation = 100%) or in combination with the antagonist compounds at various doses to determine IC50 values. Nuclear translocation and cell


















































Figure 3 (See legend on next page.)
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Figure 3 Androgen receptor level increases upon small molecule antagonism. (A) AR mRNA expression in VCaP cells (vehicle control and
Compound 30, 10 μM) from four microarray probesets (The SAM q-value of differential expression are 0, 0.037, 0.043 and 0.056 respectively). The
profiling experiment was performed using three independent biological replicates. (B) AR expression in tumors derived from VCaP cells implanted
in CB17/lcr-Prkdc SCID mice and treated with Compounds 26 and 30 as measured by quantitative RT-PCR. n = number of animals per group;
mpk=milligram per kilogram. Compound 26- and 30-treated groups were significantly different from Vehicle-group (###, *** P< 0.001). (C) AR
expression in VCaP cells treated in triplicate for 48 hr with 25 nM of either control/non-targeted siRNA (Neg-siRNA, Dharmacon Cat# D-001810-10)
or AR-siRNA pool (Dharmacon Cat# L-003400-00) as measured by quantitative RT-PCR. AR-siRNA treated samples were significantly different from
control/non-targeted ones (P = 3.49e-5).
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relation was 0.60 for fold changes and 0.56 for SAM
d-scores (P< 2.2e-16 for both; Figure 2C), indicating a
high degree of concordance between the two types of
treatments. There was also striking overlap in signifi-
cantly differentially expressed genes (P = 1.48e-11 for
up-regulated and P= 4.52e-11 for down-regulated ones
respectively). Thus, the small molecule antagonist(A)
(B)
Figure 4 Effect of AR antagonist treatment on prostate cancer cell via
percentage of control treatment. Each data point represents the mean of a
represent standard deviation of the mean (SEM). * P< 0.05; ** P< 0.01; ***
Inhibition (TGI) and PSA inhibition obtained from VCaP xenograft SCID mic
The differences between both compound-treated groups and vehicle-treat
onward [Compound 30: *** P< 0.001 for all measurements; Compound 26
measurements). PSA levels: Compound 30-treated group was significantly d
89; Compound 26-treated group was significantly different (### P< 0.001)
GraphPad Prism).induces similar global transcriptional effects as AR in-
hibition by siRNA.
Interestingly, the mRNA level of the androgen re-
ceptor itself was notably higher in compound-treated
cells compared to vehicle control across all four pro-
besets for the gene on microarray (The SAM q-value
of differential expression are 0, 0.037, 0.043 and
0.056 respectively; Figure 3A), suggesting that thebility and tumor growth inhibition. (A) Number of live cells as a
t least three independent assays performed in duplicates. Bars
P< 0.001 (two-way ANOVA, GraphPad Prism). (B) Tumor Growth
e treated for 3 months with Compounds 26 and 30. Tumor volume:
ed control were statistically significant from Day 49 of treatment
: ## P< 0.01 at day 53 and ### P< 0.001 for the rest of the
ifferent (*** P< 0.001) from vehicle-treated control on Days 74, 83 and





























Figure 5 AR binding upon small molecule antagonism. (A) Number of high-confidence AR binding sites in various conditions. (B) Percent (%)
impact of AR antagonists with increasing dosage. To quantify the molecular effects of AR antagonists, “maximum” and “minimum” AR binding
were defined using non-antagonist-treated R1881(+) and R1881(−) cistromes and the % impact was based on their differentially occupied sites.
(C) AR antagonists preferentially disrupted weaker binding sites. R1881(+)-defined binding sites were sorted by descending MACS binding score
(in cases of a tie, they were further sorted by descending fold enrichment values), which approximates binding affinity. (D) AR antagonists had a
greater effect on weaker binding sites. Fold changes were computed as −1/signal ratio and plotted as moving average with a window size of
100. Shown in black are linear trend lines. (E) Motif score distribution of the 15 bp perfect palindrome (Additional file: 1 Fig. S3B) for AR-bound
sequences and 100 groups of randomly selected comparable sequences. The binding sites still occupied in the presence of the AR antagonists
tend to have higher quality sequence motif (P< 0.01 for both compounds).
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pression in a positive feedback loop. The microarray-
based observation was further supported by RT-PCR




Compound 30 (25mpk) 38946 2520
Compound 26 (100mpk) 11324 622from the VCaP cells implanted in mice (P< 0.001;
Figure 3B), in sharp contrast to siRNA-treated cells
where AR mRNA level was significantly reduced
(P = 3.49e-5; Figure 3C).ounds on day 60, 4 hrs postdose, following daily oral
Fold Free Cp/IC50
AR antagonism VCaP proliferation
18 27
11 14
Figure 6 Signature enrichment analysis of drug-modulated direct activation (top panel) and repression targets (bottom panel) of AR.
Shown are enriched gene signatures, with size of each node proportional to number of genes in the signature and width of each line
proportional to statistical significance of the overlap between the signatures at the two ends. The signatures were colored by related biological
concepts. Direct_AR-activation/Compound30-down_regulated targets refer to genes whose associated AR binding are impacted as well as mRNA
level are significantly down-regulated upon Compound 30 treatment. Direct_AR-repression/Compound30-up_regulated targets refer to genes
whose associated AR binding are impacted as well as mRNA level are significantly up-regulated upon Compound 30 treatment.
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To determine the impact and specificity of AR antag-
onist treatment on prostate cancer growth, we first
assessed the effect of Compound 26 and 30 on cell
viability using various pre-clinical models, including
AR-positive VCaP cells and AR-negative DU145 and
PC3 cells. Proliferation of cells treated in culture forup to seven days in the presence of these small mol-
ecule antagonists was significantly inhibited in VCaP
compared to vehicle control, but was not significantly
affected in those cells which do not express AR
(Figure 4A), demonstrating that the antiproliferative
effects elicited by the antagonist compounds were AR
specific. Nevertheless, the behavior of the two
Zhu et al. BMC Genomics 2012, 13:355 Page 12 of 19
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30 dose-dependently inhibited cell proliferation, Com-
pound 26’s impact plateaued at the highest concentra-
tion tested (10 μM).
A genome-wide inhibition map of AR binding by
small molecules
Finally, we profiled the AR cistrome in the presence of
Compounds 26 and 30 at three different doses,
0.1 μM, 1 μM and 10 μM. Addition of the inhibitors
reduced the number of AR binding sites compared to
those of R1881(+) sample untreated by antagonist
(Figure 5A). Consistent with their anti-proliferative be-
havior (Figure 4A), Compound 30 had a strong dose-
dependent effect on AR binding while Compound 26’s
impact saturated at 10 μM (Figure 5A), providing a direct
molecular basis for deciphering the activity of these
small molecule-based AR therapeutics.
To quantify the molecular effects of the two antago-
nists, we defined “maximum” and “minimum” AR bind-
ing using R1881(+) and R1881(−) cistromes in the
absence of drug treatment respectively. The percent (%)
impact measure was based on their differentially occupied
sites. Strikingly, at 10 μM, Compound 30 achieved a 99%
impact, reducing AR binding essentially from maximum
to minimum level (Figure 5B) with a binding pattern simi-
lar to that of R1881(−) (Figure 5C). When sorted by their
MACS binding score, a clear trend emerged that weaker
sites were disrupted at lower dose (Figure 5C) and experi-
enced greater changes (Figure 5D). Furthermore, the
binding sites still occupied in the presence of the AR
antagonists tend to have higher quality sequence motif
of the 15 bp perfect palindrome that we identified
(Figure 5E). To address the possibility that these pat-
terns could arise because weaker binding sites are more
prone to false positives, we included eleven sites from
the lower half of the binding score spectrum for quanti-
tative PCR analysis and they were all validated (Table 1).
The AR-antagonists were also evaluated for their
in vivo efficacy in castrated VCaP tumor-bearing-
CB17/lcr-Prkdc SCID mice treated with 25 mg/kg of
Compound 30 and 100 mg/kg of Compound 26 daily by
oral gavage. The compound doses were chosen to
achieve average plasma exposure at least 10-fold higher
than the target potency of the compounds (Table 3). As
shown in Figure 4B, both AR antagonists effectively
inhibited tumor growth and reduced PSA levels
throughout the study (P< 0.001).
A core set of direct downstream effectors modulated by
AR antagonism
To obtain a multi-layer mechanistic understanding of the
action of these AR modulators, we investigated the
coupled expression change of those genes whoseassociated AR binding were impacted upon Compound 30
treatment. Notably, not only a significant number of them
were down-regulated (P= 3.10e-10) but also many were
up-regulated (P= 8.21e-4) in mRNA level upon small mol-
ecule antagonism, indicating that the compound influ-
ences direct AR targets from both modes of regulation.
Our integrative analysis of cistrome and transcriptome
data identified 195 direct activation targets and 306 direct
repression targets of AR modulated by the drug-like com-
pound respectively (Additional file 4: sFile 2). Although
often overshadowed by its activation targets, the large
number of direct repression targets suggests that andro-
gen receptor also has a major role in negative gene regula-
tion, which likely makes important contributions to its
oncogenic mechanisms as well as the activities of targeted
therapies. In fact, AR binding sites associated with direct
repression targets were no less and even slightly more
conserved than those associated with activation targets
(P= 3.64e-2), underscoring their functional relevance. Sys-
tematic pathway mapping of drug-modulated direct AR
target genes revealed that activation targets were over-
represented in cell cycle, DNA replication, and steroids
biosynthesis pathways, whereas repression targets were
over-represented by those involved in hypoxia response,
mTOR signaling and sulfur metabolism (Figure 6).
The direct activation targets of AR impacted upon an-
tagonism include many members of its own nuclear re-
ceptor (NR) family (Figure 6; P = 9.60e-4) such as
NROB1 (DAX1), NR2F1 (COUP-TF1) and THRB, re-
vealing extensive crosstalk and potential hierarchical
topology within the NR network. DAX1 has been
reported to inhibit AR function [30] and there is a high-
confidence physical interaction between the two proteins
[31]. DAX1 is also known as a negative regulator of
many genes in the steroid biosynthetic pathway [32,33].
Together, they suggest a feedback loop where an AR-
DAX1 protein-protein interaction may serve to sense
and prevent the over-production of DAX1 by AR while
AR and DAX1 counter-balance each other’s effect on
steroid synthesis (Additional file 1: Figure S4).
Emerging clinical data suggest that (metastatic) pros-
tate tumors have increased expression of enzymes
involved in steroid synthesis and lower levels of andro-
gen inactivating enzymes compared to normal tissue
[34]. As steroids are often inactivated by sulfation
[35,36], our finding of direct regulatory links from AR
to steroidogenesis and sulfur metabolism not only pro-
vides a mechanism underlying the observed gene ex-
pression changes in patient samples but also suggests an
important new dimension to AR’s pathological function
in CRPC. The down-regulation of steroid biosynthesis
and up-regulation of sulfur metabolism by small mol-
ecule antagonists observed in this study suggests that
these oncogenic activities of the androgen receptor can
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contribute to their therapeutic benefit in the clinic.
Interestingly, we observed a significant enrichment of
the drug-modulated direct AR-activation targets among
genes with higher expression in ER- breast tumors, while
conversely, the direct AR-repression targets were signifi-
cantly enriched among genes with higher expression in
ER+ breast tumors (Figure 6). Furthermore, estrogen re-
sponse elements were disproportionately distributed to-
wards binding sites near direct repression targets of AR
compared to their activation counterparts (P = 0.0049;
Additional file 3: Table S4). These point to a potential
negative functional relationship between androgen and
estrogen (related) receptors, where ER/ERR may mediate
AR’s function in transcriptional repression.
Discussion
Androgen receptor is a central player throughout devel-
opment of prostate cancer, even after androgen depriva-
tion therapy [2]. By comparing wild-type AR binding in
the absence and presence of its ligand agonist metribo-
lone, we found that AR bound to regulatory DNA ele-
ments even when androgen levels were low via selective
occupancy of the strongest binding sites (Figure 1),
offering molecular evidence for active AR signaling in
CRPC tumors [2]. It complements other reported mech-
anisms for persistent AR signaling including receptor
amplification or mutation [2-4,37,38], intratumoral con-
version of weak adrenal androgens [39] and de novo ster-
oid synthesis from cholesterol [40-42].
Previously published ChIP-Seq studies for androgen
receptor [10-13] have focused on its binding in the ab-
sence of pharmacological intervention. Here, we char-
acterize the dose-dependent effects of inhibition by
drug-like small molecules on genome-wide AR binding:
insights from this landscape can support the develop-
ment of AR therapeutics because it provides a molecular
basis for deciphering their pre-clinical and clinical activ-
ities. Both Compounds 26 and 30 (Figure 2A) are potent
AR antagonists that also inhibit AR’s translocation from
the cytoplasm to the nucleus (Figure 2B and Table 2).
Interestingly, their molecular effects on the AR cistrome
(Figures 5A and B) were consistent with corresponding
phenotypic anti-proliferative behavior (Figure 4A), indi-
cating a direct cistrome-activity relationship for these
AR antagonists. Weaker sites or those with lower quality
sequence motif of the 15 bp perfect palindrome appeared
preferentially and more impacted (Figures 5C–E). Weaker
transcription factor binding not only occurs abundantly
in vivo but may also be functionally important features of
the genomic regulatory program as revealed by evolution-
ary and gene expression analyses [43]. Our observations
here further suggest that they may also be relevant in atherapeutic context and underscore the need to look be-
yond the strongest binding sites.
Given that our drug-like inhibitors act exclusively as AR
antagonists, we not only identified a core set of direct
downstream effector genes for androgen receptor by inte-
grating cistrome and transcriptome profiling data upon
compound treatment, but also characterized their asso-
ciated mode of regulation (Additional file 4: sFile 2). Im-
portantly, these are candidate mediators in a therapeutic
setting since both AR’s binding and transcriptional activ-
ities at these loci were modulated by small-molecule
antagonists. Unbiased pathway mapping further revealed
AR as a key regulator of steroidogenesis (Figure 6). Emer-
ging data indicates that prostate tumor cells are capable
of synthesizing their own androgens to sustain growth
[44]: for instance, the expression of enzymes involved in
de novo steroid synthesis has been reported to be up-
regulated in both (metastatic) prostate tumors [34] and
CRPC patients after CYP17A1 inhibitor treatment [40].
We found AR directly regulates several key players
(Additional file 3: Table S5), a novel oncogenic mechanism
that would be relieved by antagonist treatment. Thus our
result supports the recently proposed combination ther-
apy strategy of treating with CYP17A1 and AR inhibitors
in a concurrent or sequential manner [44].
AR also appears to directly and positively modulate
the expression of its own nuclear receptor family
(Figure 6): the most notable is NROB1 (DAX1), an or-
phan nuclear receptor and a global regulator of
hypothalamic-pituitary-adrenal/gonadal axis (HPAG)
ontogenesis and steroidogenesis [32]. DAX1 inhibits
the activity of steoidogenic factor (SF-1) by directly
binding to its own promoter, preventing SF-1 mediated
transcription and hence interfering with hormone syn-
thesis [30]. DAX-1 also prevents ligand-activated AR
from being imported into the nucleus via a nucleocyto-
plasmic shuttling mechanism. Together with our obser-
vations above, AR and DAX1 appear to form a tightly
controlled feedback loop in controlling steroid biosyn-
thesis (Additional file 1: Figure S4). To add to the com-
plexity of the AR-DAX1-steroidogenesis network, it has
also been reported that the DAX1 promoter has a re-
dundant region that creates a binding site for SF-1 and
NR2F2 (COUP-TF1) [45], the latter of which is another
NR member identified as a direct AR activation target
in our current study (Figure 6).
The drug-impacted direct repression targets of AR
were significantly enriched with those related to sulfur
metabolism (Figure 6) such as SULT2B1 and PAPSS1
(Additional file 3: Table S5). SULT2B1 is involved in sul-
fation of the steroids dehydroepiandrosterone (DHEA)
and delta(5)-androstenediol [Delta(5)-Adiol] to prevent
their conversion to more potent androgens/estrogens, and
its inhibition leads to increased cell proliferation [35].
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sulfate donor (3’-phosphoadenosine 5’-phosphosulfate,
PAPS), a cofactor that inactivates steroid hormones
through sulfation [46,47]. Also directly repressed by AR
is ACOX2 (Additional file 3: Table S5), a branched-
chain acyl-CoA oxidase enzyme that takes part in the
degradation of long branched fatty acid and bile acid
intermediates in peroxisomes and is down-regulated in
castration-resistant prostate cancer [48]. These observa-
tions are particularly interesting given the clinical data
that metastatic prostate cancer express lower levels of
androgen inactivating enzymes [34] and complement
the result described above that AR positively regulates
the expression of many genes involved in biosynthesis
of steroids.
We found an inverse functional relationship between
androgen and estrogen (related) receptors in VCaP cells,
with ER/ERR likely contributing to AR’s role as a tran-
scriptional repressor (Figure 6, Additional file 3: Table S4).
Whereas AR has recently been reported to inhibit ER [49],
our study reveals a novel reciprocal effect, providing
further support for crosstalk and counter-balance be-
tween the two families of sex steroid hormone recep-
tors. It remains to be determined whether ER/ERR
contributes to AR repression by direct competition for
DNA binding or through interaction with its cofactors.
In addition to the well-established association of ERs
with breast cancer, emerging data suggest that they also
play important roles in prostate cancer. For instance,
ERβ, localized in prostate epithelial cells together with
AR and DAX1, is pro-apoptotic, anti-proliferative and
anti-inflammatory and impedes prostate cancer EMT
[50,51]. ERβ agonists were shown to activate apoptosis
through tumor necrosis factor-α (TNF-α) signaling and
target cells that are resistant to systemic androgen
deprivation [52]. Additionally, the closely related or-
phan nuclear receptor ERRβ has been reported to be
down-regulated in prostate cancer cells and carcinoma
lesions and it performs as a tumor suppressor [53].
While stable ERRβ expression suppressed in vivo pros-
tate tumor growth, treatment with an ERR agonist
potentiated ERRβ-induced growth inhibition of prostate
cancer cells. Lately the many similarities between breast
and prostate cancer have become widely appreciated
[49], leading to important therapeutic implications, such
as a phase II clinical trial that is currently underway to
investigate the potential benefit of targeting AR in triple
negative breast cancer [54].
Our observation that the expression of the drug target
itself (androgen receptor) was significantly up-regulated
upon small molecule antagonism (Figures 3A and B)
points to an interesting feedback loop of how cells react
to AR inhibition. This pattern appears to be a recurrent
theme in molecular drug responses: for example, veryrecently it was reported that CYP17A1 level was markedly
increased in tumor biopsies from CRPC patients after
CYP17A1 inhibitor therapy [40]. Further characterization
of this control structure, especially in terms of network
properties, may elucidate a general mechanism under-
lying antagonist drug response and associated clinical
outcome.
Conclusions
Our study charts the dose-dependent effects of small-
molecule antagonists on the genomic landscape of AR
binding and elucidates their relationship with phenotypic
and transcriptional activities. These novel insights into
modulation of the AR regulatory program upon thera-
peutic antagonism provide a molecular platform for
deciphering and developing next generation of pharma-
cological agents targeting the androgen receptor.
Methods
Accession numbers
The NGS and microarray data have been deposited in the
NCBI Sequence Read Archive (SRA) and Gene Expression
Omnibus (GEO) [SRA: SRP008849, GEO: GSE32892].
Cell culture
VCaP human prostate cell lines were obtained from
ATCC and grown in DMEM (GIBCO Cat# 11995) 10%
FBS (SIGMA Cat# 12103 C-500 ml). Medium was supple-
mented with standard antibiotics (Penicillin-Streptomycin,
GIBCO #15070-063).
Transactivation assay
AR trans-activation assay was performed as previously
described [28]. Briefly, LNCaP cells were engineered to
over-express wild type human AR and to express an
ARE2-PB-Luc reporter (LNAR cells). Cells were starved
for 3 days prior to performing trans-activation assays, in
phenol red free (PRF)-RPMI Medium supplemented
with 5% of charcoal stripped FBS. On the day of the
assay, cells were seeded at a density of 5,000 cells/well in
96 well plate in starvation medium and 4 hr later treated
with the compounds in the absence (agonistic mode) or
presence (antagonistic mode) of 100pM R1881 for 24 hr.
Luciferase readings were acquired by means of a Perkin
Elmer EnVision Excite Multilabel Reader (Ultra Sensitive
Luminescence method).
AR nuclear translocation
LNAR cells were starved for two days in phenol red free
RPMI medium containing 5% charcoal-dextran stripped
FBS (Omega Scientific) prior to the assay. For Nuclear
Translocation (NT) assay, 3,000 cells per well (in 384
well plates) were treated with compounds and 100pM
R1881. Following overnight incubation the cells were
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containing 0.5% Triton X-100 and blocked with 1% BSA.
Cells were then stained with anti-AR monoclonal anti-
body (Abcam) followed with alexa 488 conjugated anti-
Mouse IgG secondary reagent (Invitrogen). Finally the
cells were counter stained with Hoechst 33342 (Invitro-
gen) and Cell mask Deep Red (Invitrogen). Plates were
sealed and imaged using an Evotec Opera high content
imager. Images were analyzed using an Acapella (Evotec)
algorithm customized by Pfizer to quantify the fluores-
cence associated with anti-AR in the cytoplasm and nu-
clear regions. The ratio of Nuclear to Cytoplasm
fluorescence was calculated and used as to tract inhib-
ition of AR translocation.
Cell viability
Cells were seeded at a density of 15,000 cells/well
(VCaP) or 1,000 cells/well (PC3 and DU145) in 96 well-
plates and treated after attachment to the plate with test
compounds. Medium and compounds were refreshed
every 2–3 days. Number of live cells was analyzed at day
7 using the Resazurin assay (SIGMA Cat# R7017).
Other treatments
Cells were starved for 3 days in phenol red free DMEM
containing 5% charcoal stripped FBS, and then seeded in
6-well plates at a density of 1 million cells per well in
starvation medium. In the case of compound treatment
(for ChIP-Seq study), cells were allowed to attach over-
night and then were treated with various doses of the
AR antagonists or vehicle alone (0.1% DMSO) in the ab-
sence or presence of 1nM R1881. Cells were incubated
for 30 min at 37°C, 5% CO2 and then processed.
For siRNA treatment, cells were seeded in DMEM con-
taining 10% FBS and transfected the day after seeding with
25nM AR-siRNA pool (Thermo Scientific, L-003400-00
-0020) using Lipofectamine 2000 reagents (Invitrogen,
11668–019) and following manufacturer’s instructions.
Cells were incubated at 37°C 5% CO2 for 48 h and then
processed.
In both procedures, after the indicated treatment time,
cells were rinsed once with ice-cold PBS and then lysed
with Qiagen RNeasy Plus Kit (Cat# 74134, Qiagen, Valen-
cia, CA). RNA quality was assessed using the Bioanalyzer
(Agilent, Sunnyvale, CA) and spectrophotometer.
Chromatin immunoprecipitation (ChIP)
ChIP was carried out by Active Motif (formerly Gen-
pathway) as follows. Cells were fixed with 1% formalde-
hyde at room temperature for 15 minutes. Fixation was
stopped by the addition of glycine to a final concentra-
tion of 0.125 M glycine. Chromatin was isolated from
the sample by adding 10 ml lysis buffer containing
PIPES, Igepal, PMSF and Protease Inhibitor Cocktail,followed by disruption with a Dounce homogenizer.
Samples were pelleted by centrifugation and resus-
pended in buffer containing sodium deoxycholate, SDS,
and Triton X-100. Lysates were sonicated using a Miso-
nix Sonicator 3000 equipped with a microtip in order to
shear the DNA to an average length of 300–500 bp.
Lysates were cleared by centrifugation and the chromatin
suspensions were transferred to new tubes and stored
at −80°C. To prepare Input DNA (genomic DNA), two ali-
quots of 10 μl each (approximately 1/50 of each chromatin
preparation) were removed and treated with RNase for
1 hr at 37°C, proteinase K for 3 hr at 37°C, and 65°C heat
for at least 6 hr to overnight for de-cross-linking. DNAs
were purified by phenol-chloroform extraction and etha-
nol precipitated. Pellets were resuspended in 1/5 TE buf-
fer. Resulting DNAs were quantified on a Nanodrop
spectrophotometer. Extrapolation to the original chroma-
tin volume allowed determination of the yield for each
chromatin preparation (as measured by the DNA
content).
Prior to use in ChIP, protein A agarose beads (Invitro-
gen) were pre-blocked using blocking proteins and nu-
cleic acids for 3 hr. For each ChIP reaction, an aliquot of
chromatin (30 μg) was pre-cleared with 30 μl pre-
blocked protein A agarose beads for 2 hr. ChIP reactions
were set up using pre-cleared chromatin and antibody
AR (Santa Cruz Biotechnology, Cat# sc-13062, Lot#
D0610) in a buffer containing sodium deoxycholate and
incubated overnight at 4°C. Pre-blocked protein A agar-
ose beads were added and incubation at 4°C was contin-
ued for another 3 hr. Agarose beads containing the
immune complexes were washed two times each with a
series of buffers consisting of the deoxycholate sonic-
ation buffer, high salt buffer, LiCl buffer, and TE buffer.
An SDS-containing buffer was added to elute the im-
mune complexes from the beads, and the eluates were
subjected to RNase treatment at 37°C for 20 min and
proteinase K treatment at 37°C for 3 hr. Cross-links
were reversed by overnight incubation at 65°C, and ChIP
DNAs were purified by phenol-chloroform extraction
and ethanol precipitation. Quality of ChIP enrichment
was assayed by qPCR using primers against known posi-
tive control site(s). Input DNA was queried at the same
sites in parallel.Sequencing
ChIP DNA was amplified by following the Illumina ChIP-
Seq DNA Sample Prep Kit protocol. In brief, DNA ends
were polished and 5’-phosphorylated using T4 DNA poly-
merase, Klenow polymerase and T4 polynucleotide kinase.
After addition of 3’-A to the ends using Klenow fragment
(3’-5’ exo minus), Illumina genomic adapters were ligated
and the sample was size-fractionated (200–250 bp) on a
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cycles, Phusion polymerase), the resulting DNA libraries
were quantified and tested by QPCR at the same specific
genomic regions as the original ChIP DNA to assess qual-
ity of the amplification reactions. DNA libraries were
sequenced on a Genome Analyzer II.
Identification of AR binding sites
Alignment of the 36-bp single-read sequences (“tags”)
from ChIP-Seq to the human genome (hg19) was con-
ducted by Active Motif with ELAND (Illumina CASAVA
1.5 pipeline) software. Tag density was calculated by divid-
ing the genome into 32-nt bins and counting the number
of 3’-end extended tags in each bin (Active Motif). Only
sequence reads that pass quality filtering, with an align-
ment score of at least 10 and perfect genomic match were
included for peak detection. AR-enriched genomic regions
(binding sites) were identified by comparing the ChIPed
samples with input sample using MACS algorithm [16]
(1.4.0rc 2) and option of “-p 1e-10”. For subsequent ana-
lyses, we used the most high-confidence regions (FDR
< 0.01) based on joint p-value score and fold enrichment
cutoffs of 500 and 20. The values were chosen in consider-
ation of “negative” peaks generated from swapping the
ChIP-Seq and control channels (These “negative” peaks
have no biological meaning and thus serve as a control for
estimating/filtering out technical noises). To enable quan-
titative comparison (e.g. fold change) of the same binding
site across samples, a “signal” measurement was computed
for it in each sample by combining tag density values for
bins that fall within the binding site with one-step Tukey's
biweight algorithm.
Quantitative PCR (qPCR) validation
Twelve AR binding sites identified from ChIP-Seq were
tested for enrichment by real-time quantitative PCR.
Reactions were carried out in triplicate. Fold enrichment
was determined relative to a non-enriched region (a re-
gion in gene desert on chromosome 12). Their primer
sequences were included in Table 1.
Mapping to genomic annotations
AR binding sites were mapped to transcriptional start sites
(TSS) of genes based on refFlat (hg19) table from UCSC
Genome Browser. The classification of AR binding sites
relative to genomic annotations (promoter/exomic/in-
tronic/intergenic) and calculation of associated enrichment
statistics were performed with RegionMiner tool and
ElDorado database (Genomatix).
Sequence conservation analysis
Sequence conservation was assessed using phastCons
conserved elements [17,18] derived from multiplealignments of 45 vertebrate genomes to the human gen-
ome. Conservation score was sampled every 100 bp from
the summit of each AR binding site (as reported by
MACS) to 10 kb in both directions. It was defined to be
the phastCons score of the overlapping conserved elem-
ent, or zero for those outside of conserved elements. To
explore the relationship between sequence conservation
and mode of AR regulation, binding sites were classified
in a binary fashion as conserved or non-conserved based
on summit position. Statistical significance of the associ-
ation was determined using two-tail Fisher’s exact test.
Motif analysis
AR bound-sequences were searched for predefined motif
matrices of transcription factors from MatBase library
v8.3 vertebrate collection using RegionMiner (Genoma-
tix). Over-representation statistics were reported as Z-
score (the distance from the population mean in units of
the population standard deviation) computed against
genomic background (NCBI37/hg19). V$GREF-V$FKHD
pair (module) is defined as two elements from 10 to
50 bp (middle to middle) of each other. Their occur-
rences were examined for distance distribution within
the range.
MEME algorithm [25] was used to discover enriched se-
quence motifs ab initio from repeat-masked AR-bound
sequences. In cases where a binding site is longer than
500 bp, only 500 bp centered on its summit were used. In
consideration of computational time, we preformed the
search with 2500 top sequences in terms of binding score.
MEME was run using “-dna -mod zoops -revcomp -evt
0.01” command line options. Specificity was assessed as
Z-score from 100 randomly sampled groups of the same
number of sequences of the same length from the same
chromosomes as AR binding sites. To investigate the en-
richment and score distribution of the above MEME-
derived ARE consensus motif, we scanned the AR-bound
sequences as well as randomly sampled genomic
sequences with its position weight matrix using PATSER
[55] (v. 3e) and command line options “-c -li -s u2” or
“-c -ls 0 -s -u2”. We determined presence/absence of
motifs as predefined vertebrate matrices from MatBase in
a similar manner (PATSER and “-c -li -s u2” option),
whereas their statistical association with mode of AR
regulation (direct activation/repression) was computed
using two-tail Fisher’s exact test.
Quantitative Reverse Transcriptase- PCR (qRT-PCR) –
in vivo samples
Approximately 20 mg of tumor samples in RNALater
were homogenized by means of Qiagen TissueLyser 2,
for 2 min @ 20 Hz. Homogenates were then processed
using Qiagen RNeasy Plus kit (Cat#74134). Samples
were resuspended in 60μL water and 2 μg RNA from
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using TaqMan RT-PCR ABI7900HT, in a two-step pro-
cedure, as following: 1) For reverse transcriptase step we
utilized ABI High Capacity cDNA Reverse Transcription
Kit (4368814,from Applied Biosystems). Cycle run was
10 min 25°C, 2 h 37°C, 5 min 85°C and cool down to 4°C.
For the qPCR reaction we utilized ABI 2X universal Mas-
ter mix (4324018, Applied Biosystems) using ddCt (RQ)
method for quantification. Cycle was 10 min 95°C, 15 s
95°C, 60s 60°C, 40 cycles. Primers used were ID#
Hs00907244-ml for for AR and # 4352934E for GADPH
(Applied Biosystems).
Tumor growth inhibition (TGI) – VCaP CRPC in vivo model
VCaP (3.5million) cells (in 50% matrigel product#
354234, lot A7141) were implanted subcutaneously in
CB17/lcr-Prkdc SCID mice, and when tumors reached
about 200 mm3 in size the animals were castrated. Since
PSA levels remain low in this in vivo model until the
tumors are significantly large (400 mm3), the re-growth
of tumors post-castration was interpreted as a sign that
the animals entered into the castration refractory phase.
Animals were then randomized based on tumor volume
and treatment commenced. In general and unless other-
wise indicated, compounds were given by oral gavage
once daily. Vehicle formulation consisted of 0.9% benzyl
alcohol, 1% Tween-80 and 98.1% methylcellulose (0.5%).
Tumor volume was calculated by the formula: length x
width x depth x 0.5236. To measure PSA, 15 μl serum
was diluted 1:3 v/v in water and then 25 μl of the dilu-
tion samples were transferred to the ELISA plate for the
assay (PSA ELISA Kit from American Qualex Antobo-
dies, Cat# KD4310). At the end of the study, animals
were sacrificed and the tumors were extracted and trea-
ted with RNALater (Qiagen, Cat# 76154). Statistic ana-
lysis was performed using two-way ANOVA (GraphPad
Prism, Version 5.01 - http://www.graphpad.com).
Expression profiling and data analysis
RNA from VCaP cells treated with AR-siRNA, Compound 30
(10 μM) or corresponding controls underwent 1st and 2nd
strand cDNA synthesis, in vitro reverse transcription, and tar-
get preparation following the GeneChip Expression Analysis
Technical Manual (Affymetrix). Overnight hybridization of
the fragmented cRNA on the GeneChipW Human Gen-
ome U133A 2.0 array and subsequent washing, staining
and scanning steps were performed as suggested by the
manufacturer (Affymetrix). Image analysis was done with
the Expression Console (Affymetrix).
Expression profiling data were RMA normalized with
“affy” package of Bioconductor, followed by exclusion of
spike-in controls (AFFX) and mixed cross-hybridization
(_x) probe sets. Significance Analysis of Microarray
(SAM) algorithm [29] implemented in “samr” packagewas used for differential expression analysis between
compound/siRNA-treated and control samples. The
fold change (FC) and d-score outputs from all probe
sets were used for computation of genome-wide correla-
tions. Significantly differentially expressed genes refer to
those with FDR< 0.05 and |FC|> 1.5. Genes with probe
sets going opposite directions were not included in sub-
sequent analyses.Gene signature enrichment analysis
Gene signature enrichment analysis was performed by
comparing direct AR- activation/repression targets
from small molecule antagonism with signatures col-
lected from a variety of public databases and studies
(e.g. MSigDB, GeneSigDB, NetPath, Gene Ontology,
KEGG). Statistical significance of signature enrichment
was determined using cumulative hypergeometric
probability distribution as previously described [56]
and correction for multiple hypothesis testing was con-
ducted with the Q-value package [57]. Some signifi-
cantly enriched signatures and their connections were
plotted with network visualization tool Pajek [58]. We
only reported enriched signatures with corresponding
FDR< 0.05.Additional files
Additional file 1: Figure S1. AR protein expression. VCaP cells were
treated in the presence of 25nM control/non-targeted siRNA or AR-siRNA
pool. The protein levels of AR were analyzed by western blot using anti-
AR (Santa Cruz Cat# sc-815). Anti-Tubulin (Santa Cruz, Cat# sc-12462-R)
was included for loading control. Figure S2. AR binding and cell type.
Overlap of the AR binding sites between VCaP cells and other cell types
from previous studies: 1(Lin et al., 2009); 2(Wang et al., 2009); 3(Massie et
al., 2011). Binding sites based on earlier version of human genome were
remapped to hg19 using UCSC liftOver tool. Overlap was defined by
sharing of at least 1 bp. Figure S3. AR binding and sequence features.
(A) Distance distribution between neighboring (10-50 bp) GREF and
FKHD elements. (B) The motif identified de novo from AR-bound
sequences appears to be a 15 bp perfect palindrome. (C) Motif and
binding strength. AR binding sites were divided into two groups based
on whether they had a significant occurrence of the palindromic motif in
(B). Boxplots depict the distributions of their binding scores. Figure S4.
AR and DAX1 form a tightly controlled feedback loop on steroid
biosynthesis: AR and DAX1 counter-balance each other’s effect on
steroidogenesis. AR also directly and positively regulates the expression
of DAX1, whereas their physical interaction may serve to sense and
prevent the over-production of DAX1 by AR. Dashed links refer to
previously reported regulatory relationships, while solid links describe
regulatory relationship identified in this study. Positive or stimulatory
effects are represented by (+), and negative or inhibitory effects are
represented by (−).
Additional file 2: sFile1. AR binding sites list.
Additional file 3: Table S1. The distribution of AR binding sites relative
to genomic annotations. Table S2. Gene signatures most enriched
among AR-bound genes. Table S3. MatBase families most
over-represented among AR-bound sequences, sorted by descending
Z-score. Table S4. Transcription factor binding motifs associated with
mode of AR regulation. Table S5. Selective drug-modulated direct
downstream effectors of AR involved in steroid metabolism.
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repression targets of AR from small molecule antagonism.
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